SE0102888D0 - New formulation - Google Patents
New formulationInfo
- Publication number
- SE0102888D0 SE0102888D0 SE0102888A SE0102888A SE0102888D0 SE 0102888 D0 SE0102888 D0 SE 0102888D0 SE 0102888 A SE0102888 A SE 0102888A SE 0102888 A SE0102888 A SE 0102888A SE 0102888 D0 SE0102888 D0 SE 0102888D0
- Authority
- SE
- Sweden
- Prior art keywords
- dosage form
- relates
- prevention
- active substance
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a new extended release oral dosage form of the good soluble pharmaceutically active substance, (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide, in the form of the free base or pharmaceutically acceptable salts and/or hydrates or solvates thereof, for use in the prevention and/or treatment of central nervous system (CNS) disorders and related medical disturbances. More particularly, the invention relates to an extended release oral dosage form that provides a defined blood concentration profile having no rapid initial rise in blood plasma concentration of the good soluble active substance when administered at low dose. The invention further relates to processes for preparing said dosage form, the use of said dosage and a method of prevention and/or treatment of CNS disorders and related medical disturbances using said dosage form.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102888A SE0102888D0 (en) | 2001-08-29 | 2001-08-29 | New formulation |
PCT/SE2002/001542 WO2003017984A1 (en) | 2001-08-29 | 2002-08-28 | A new extended release oral dosage form |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102888A SE0102888D0 (en) | 2001-08-29 | 2001-08-29 | New formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0102888D0 true SE0102888D0 (en) | 2001-08-29 |
Family
ID=20285179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0102888A SE0102888D0 (en) | 2001-08-29 | 2001-08-29 | New formulation |
Country Status (2)
Country | Link |
---|---|
SE (1) | SE0102888D0 (en) |
WO (1) | WO2003017984A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1523981A1 (en) * | 2003-10-13 | 2005-04-20 | Wyeth | Extended release formulations of venlafaxine |
CA2652576A1 (en) * | 2006-05-19 | 2007-11-29 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of viral infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE457505B (en) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION |
US4837032A (en) * | 1986-02-04 | 1989-06-06 | Farval Ag | Theophylline sustained release tablet |
GB8624213D0 (en) * | 1986-10-09 | 1986-11-12 | Sandoz Canada Inc | Sustained release pharmaceutical compositions |
PE57198A1 (en) * | 1996-03-25 | 1998-10-10 | American Home Prod | PROLONGED RELEASE FORMULA |
SE510305C2 (en) * | 1997-05-30 | 1999-05-10 | Astra Ab | Fresh salt |
MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
-
2001
- 2001-08-29 SE SE0102888A patent/SE0102888D0/en unknown
-
2002
- 2002-08-28 WO PCT/SE2002/001542 patent/WO2003017984A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2003017984A1 (en) | 2003-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065638L (en) | Controlled-release formulations containing vardenafil | |
BR0205722A (en) | Prolonged release formulation and method for treating a patient suffering from pain | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
ATE381537T1 (en) | FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | |
DK1256339T3 (en) | Transdermal therapeutic system for obtaining high plasma levels of rotigotine in the treatment of Parkinson's disease | |
IS6970A (en) | Solid formulation comprising 4-cyano-trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide and PVP | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
HUP0203716A2 (en) | Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect and pharmaceutical compositions containing them | |
SE0102440D0 (en) | New compound | |
MXPA01008993A (en) | Combination treatment for depression and anxiety. | |
EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
SE0102887D0 (en) | New formulation | |
HUP0300863A2 (en) | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide, process for producing it and pharmaceutical composition containing it | |
NZ535611A (en) | Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist | |
HUP0204391A2 (en) | The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders | |
SE0102888D0 (en) | New formulation | |
SE9702066D0 (en) | A new salt | |
SE0102886D0 (en) | New formulation | |
TW200502002A (en) | A new oral immediated release dosage form | |
DE60221104D1 (en) | SUBSTITUTED DIARYL HARVES AS STIMULATORS OF FAS-MEDIATED APOPTOSIS | |
HUP0402062A2 (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them | |
HUP0301408A2 (en) | Methods and compositions using sulodexide for the treatment of diabetic nephropathy | |
HK1075390A1 (en) | Citalopram for the treatment of elevated blood pressure | |
SE0002354D0 (en) | New formulation | |
MX2022006535A (en) | Treating behavioral and psychological symptoms in dementia patients. |